NewsBenzingaMoleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Benzinga 2026.10.30 12:43 (GMT+0) Open on Benzinga Other news Diodes Sees Q4 Adj EPS $1.25-$1.45 vs $1.03 Est; Sees Sales $533.500M-$566.500M vs $505.967M Est Leerink Partners Maintains Market Perform on Amgen, Raises Price Target to $464 Drilling Tools Intl Q3 Adj. EPS $(0.01) Misses $0.04 Estimate, Sales $40.645M Miss $40.871M Estimate Lyft Q3 EPS $(0.03) Misses $0.18 Estimate, Sales $1.822B Miss $1.920B Estimate Nyxoah Q3 EPS $(0.20) Beats $(0.24) Estimate, Sales $10.554M Miss $11.110M Estimate eGain Sees Q2 GAAP EPS $(0.02)-$0.01 vs $(0.03) Est
